Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07871838
NA

Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

View on ClinicalTrials.gov

Summary

Clinical experience with hypo fractionated radiotherapy to date has shown that it is a safe and effective way to treat many types of cancer. Hypo fractionation means that the patient receives a total of 5 radiation treatments every other day, rather than 25 treatments over 5 weeks. The goal of this study is to find out how safe this special kind of radiation technique is for women with endometrial cancer, both right after the treatment and later on. We also want to see how well this treatment works in stopping the cancer from coming back and how it affects the patients' overall health and quality of life. The main question it aims to answer is: How does this particular type of radiotherapy affect the patients in terms of short and long term side effects? Participants will: * Visit the clinic for a total of 15 times in 60 months for check ups * Complete a total of 9 questionnaires throughout the 15 visits * Have standard-of-care blood tests and imaging to monitor the cancer response to treatment

Official title: Hypofractionated Endometrial Radiation Outcomes and Safety

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2025-03-07

Completion Date

2035-08

Last Updated

2026-10-13

Healthy Volunteers

No

Interventions

RADIATION

Hypo fractionated RT

The patients will receive whole pelvic radiotherapy (WPRT) to a total dose of 28.5 Gy in 5 fractions in alternate days (BED 64.6 Gy), delivered by RapidArc. Vaginal brachytherapy boost, 6 Gy in 1 fraction, is allowed in patients with cervical stroma involvement

Locations (1)

McGill University Health Centre--Cedars Cancer Centre

Montreal, Quebec, Canada